Unlike the effectiveness of GLP-1 agonist studies on NAFLD, most studies showed that a DPP-4 inhibitor led to little improvement in patients with diabetes and NAFLD [46]. This evidence concerns the gene GCG and metabolic dysfunction-associated steatotic liver disease.